Related Experiment Video

Updated: Sep 27, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

B-type natriuretic peptide for diagnosis and treatment of congestive heart failure

Gabriela M Kuster1, Hildegard Tanner, Gert Printzen

  • 1Swiss Cardiovascular Center, Institute of Clinical Chemistry, University Hospital, Bern, Switzerland.

Swiss Medical Weekly
|February 15, 2003
PubMed

Insights

B-type natriuretic peptide (BNP) levels effectively indicate congestive heart failure (CHF) severity and predict adverse events. BNP correlates with clinical status, cardiac function, and exercise capacity, aiding in patient stratification and management.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Management

Background:

  • Prognostic classification of congestive heart failure (CHF) is challenging.
  • B-type natriuretic peptide (BNP) is a known diagnostic and prognostic marker for CHF patients.
  • This study evaluates the clinical utility of BNP for CHF patient stratification and treatment.

Purpose of the Study:

  • To assess the clinical value of BNP in stratifying patients with CHF.
  • To evaluate the role of BNP in managing CHF patients.
  • To determine the correlation between BNP levels and clinical parameters in CHF.

Main Methods:

  • 33 outpatients with CHF were included, with measurements of BNP, sodium, 6-minute walking test (6MWT), echocardiography (LV ejection fraction, LVEDD, LVM), and heart catheterization (LVEDP, SVR).
  • BNP was measured at admission and discharge for hospitalized patients.
  • A 1-year follow-up was conducted to assess adverse clinical events.

Main Results:

  • Higher NYHA class correlated with significantly higher BNP levels (p = 0.002).
  • BNP showed significant correlations with LVEDP, SVR, 6MWT, LVEF, and sodium levels.
  • Patients with adverse events during follow-up had significantly higher BNP levels compared to those with favorable outcomes (p < 0.001).

Conclusions:

  • BNP levels correlate strongly with CHF clinical severity (NYHA class).
  • BNP is directly related to cardiac filling pressures (LVEDP), left ventricular function (LVEF), and exercise performance (6MWT).
  • BNP demonstrates prognostic value for predicting adverse clinical events in CHF patients.
Abstract

More Related Videos

Nitropeptide Profiling and Identification Illustrated by Angiotensin II07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: